PRTA - MCAP CO - Prothena Corporation

Prothena Corporation (PRTA) develops targeted antibodies to combat protein misfolding disorders in the body. The company leverages advanced protein mapping techniques to overcome Alzheimer's and Parkinson's pathologies. The current metric stands at 0.43. High scientific authority and the support of major partners validate the platform's potential, as clearly demonstrated by the asset price chart below.

Fundamental asset screening begins by determining the total business value, a metric calculated as the product of the current share price and the number of outstanding securities. By analyzing the issuer's market value chart, an investor assesses the company's actual stability, separating speculation from growth. For Prothena Corporation (PRTA), this metric reflects market expectations for the therapy of neurodegenerative pathologies. Market capitalization will increase following the commercial launch of drugs targeting Alzheimer's disease.